AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05071781
Drug: Corticotropin-release hormone
RxNorm normalized name: corticotropin-releasing hormone
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a bolus dose (CRH 100 µg or placebo) will be administered, followed by a continuous infusion (CRH 1 µg/kg/h or placebo)
Trial: NCT04527224
Drug: AstroStem-V
RxNorm normalized name: AstroStem-V
DrugBank: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins (DB15729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogenic adipose tissue-derived mesenchymal stem cells (AdMSCs)
Trial: NCT03544060
Drug: Volanesorsen
RxNorm normalized name: Volanesorsen
DrugBank: Volanesorsen (DB15067)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Volanesorsen administered by subcutaneous (SC) injections in the abdomen, thigh, or upper arm.
Trial: NCT06026254
Drug: Immune Checkpoint Inhibitor
RxNorm normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered according to product label
Trial: NCT00377065
Drug: raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: raltegravir 400 mg P.O. bid tablet twice daily for 12 weeks
Trial: NCT06707012
Drug: Metformin Hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will be divided in 2 groups~1 group will receive metformin and 2nd group will receive placebo
Trial: NCT06303037
Drug: Remimazolam besylate and low-dose Esketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esketamine was injected intravenously 0.25mg/kg and the initial dose of Remimazolam was 0.3mg/kg
Trial: NCT06303037
Drug: Remimazolam besylate and Medium dose Esketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esketamine was injected intravenously 0.5mg/kg and the initial dose of Remimazolam was 0.2mg/kg
Trial: NCT06712316
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT06712316
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT06712316
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous infusion
Trial: NCT06712316
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT06707142
Drug: TBD11
RxNorm normalized name: Tirbanibulin
DrugBank: Tirbanibulin (DB06137)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: TBD11 will be administered orally.
Trial: NCT05558462
Drug: XC8
RxNorm normalized name: Xylazine
DrugBank: Xylazine (DB11477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of R or T drug in each of 2 periods of the study in fasted conditions
Trial: NCT05943977
Drug: MB-102 DMID
RxNorm normalized name: MBS
DrugBank: Morpholinylmercaptobenzothiazole (DB14202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 130 mg of the MB-102 Domestic Manufactured Investigational Drug administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered over 30-60 seconds.
Trial: NCT05943977
Drug: MB-102 OMID
RxNorm normalized name: MBS
DrugBank: Morpholinylmercaptobenzothiazole (DB14202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 130 mg of the MB-102 Overseas Manufactured Investigational Drug (OMID) administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered over 30-60 seconds.
Trial: NCT06639347
Drug: SHR-A2102
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-A2102
Trial: NCT06639347
Drug: Adebrelimab injection
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab injection
Trial: NCT06639347
Drug: SHR-8068 injection
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-8068 injection
Trial: NCT05846724
Drug: Pembrolizumab + Lenvatinib
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: single-arm study of pembrolizumab plus lenvatinib
Trial: NCT06684327
Drug: Albumin-paclitaxel Injection
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participant will receive albumin-paclitaxel 260mg/m2 d1, isocyclophosphamide 1500mg/m2 d2-5, and cisplatin 25mg/m2 d2-5 every 21 days until disease progression, intolerable toxicity, or full 6 cycles of treatment, whichever occurs first.
Trial: NCT06687967
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
Trial: NCT06565338
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: drug
Trial: NCT06565338
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug
Trial: NCT04794699
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT04794699
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT04794699
Drug: Sacituzumab govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous infusion
Trial: NCT06714708
Drug: Active comparator
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Sintilimab, 200mg IV D1 Q3W Drug: Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5-6mg/ml/min D1 IV Q3W Drug: Pemetrexed, 500mg/m2 D1 IV Q3W or Albumin paclitaxel 260mg/m2，D1 or 130mg/m2，D1,8 IV Q3W
Trial: NCT05039268
Drug: 3K3A-APC Protein
RxNorm normalized name: Recombinant human activated protein C (rH-APC)
DrugBank: Drotrecogin alfa (DB00055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3K3A-APC with intravenous dosing of five doses of either 15mg or 30mg at 12 hourly interval. The first 8 patients will receive 15mg dose, and the next 8 patients will receive 30mg dose.
Trial: NCT06057402
Drug: Elranatamab
RxNorm normalized name: ELRANATAMAB
DrugBank: Elranatamab (DB15395)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elranatamab is a heterodimeric humanized full-length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells
Trial: NCT06718101
Drug: Lutikizumab
RxNorm normalized name: Lutikizumab
DrugBank: Lutikizumab (DB16224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) Injection
Trial: NCT06719180
Drug: Bupivacain
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection into the vaginal cuff will occur before vaginal cuff closure with stratafix suture. There will be four points of injection 1cm from the edges of the vaginal cuff with a sterilized needle to a depth of 3-4cm. 5cc of bupivacaine with epinephrine or 5cc of normal saline will be injected into each area
Trial: NCT06677957
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin will be administered together with Rosuvastatin as a drug cocktail as specified for the respective period
Trial: NCT06677957
Drug: Divarasib
RxNorm normalized name: Divarasib
DrugBank: Divarasib (DB17488)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divarasib will be administered in combination with Digoxin and Rosuvastatin as specified for the respective period
Trial: NCT06281327
Drug: Avatrombopag
RxNorm normalized name: AVATROMBOPAG
DrugBank: Avatrombopag (DB11995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After enrollment, all subjects receive Avatrombopag treatment. The initial dose of Avatrombopag administration was an oral 10 mg (\<30kg) or 20mg (≥30kg) once daily in all participants. ps. For subjects weighing ≥30kg, the dose can be started from 40mg once daily if the platelet count is \< 10×10\^9/L or if there is severe bleeding or risk of bleeding.~Complete blood count including platelet count was done once a week. The dose of Avatrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count was less than 30×10\^9/L for 2 weeks, avatrobopag was gradually increased. If the platelet count was greater than 150 x 10\^9/L, avatrobopag was gradually reduced. If the platelet count \>250×10\^9/L, avatrobopag will be stoped until the platelet count \<100×10\^9/L.
Trial: NCT06706401
Drug: Vesanoid
RxNorm normalized name: Vesanoid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before (chemo)radiotherapy: D1 to D3: 150mg/m2/day, 1 week before radiotherapy. Post (chemo)radiotherapy: D1 to D3: 150mg/m2/day every 3 weeks for up to 4 cycles post (chemo)radiotherapy
Trial: NCT06706401
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin is recommended for the following patients : Stage T1-T2/N2a-N2b and T3/N0-N1-N2a-N2b. concomitant chemotherapy is standard of care treatments and should be administered as per standard practice.~Chemotherapy will include one of the two cisplatin regimens specified in this protocol at the discretion of the participating centers. The centers must however treat all their recruited patients with one of the two regimens chosen before site activation. Chemotherapy should start the first day of radiotherapy. Cisplatin should be infused before radiation therapy delivery.~The 2 options are:~• Cisplatin 100 mg/m² i.v. on day 1 and 22 of radiotherapy (when 70 Gy are delivered in 6 weeks) or on day 1, 22 and 43 (when 70 Gy are delivered in 7 weeks).~or~• Cisplatin 40 mg/m² i.v. on day 1, 8, 15, 22, 29, 35 of radiotherapy (when 70 Gy are delivered in 6 weeks) or on day 1, 8, 15, 22, 29, 35, 42 of radiotherapy (when 70 Gy are delivered in 7 weeks).
Trial: NCT06706401
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab is recommended for the following patients : Stage T1-T2/N2a-N2b and T3/N0-N1-N2a-N2b. concomitant Cetuximab is standard of care treatments and should be administered as per standard practice.~Cetuximab therapy will be started with an intravenous loading dose of 400 mg/m2 one week before start of RT followed by six (radiotherapy over 6 weeks) or seven (radiotherapy over 7 weeks) weekly doses of 250 mg/m2.
Trial: NCT06704516
Drug: Menopausal hormone therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Any brand, composition, route and dose of systemic menopausal hormone therapy containing oestrogen.~Brands of HRT include oestrogel, Evorel, Lenzetto, Estradot, Progynova (this list is not exhaustive)
Trial: NCT06705088
Drug: SUVN-I6107
RxNorm normalized name: SUVN-502
DrugBank: SUVN-502 (DB06140)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUVN-I6107 Tablet
Trial: NCT04750616
Drug: Niacinamide
RxNorm normalized name: Niacinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Niacinamide 3 grams on the day of surgery and post-surgical days one and two
Trial: NCT01419366
Drug: Torrent's Donepezil Hydrochloride Tablets 10mg
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05632133
Drug: Lacosamide 50 MG Oral Tablet
RxNorm normalized name: LACOSAMIDE 50 mg ORAL TABLET
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving 50 mg lacosamide Bid and Ibuprofen 200-400 mg only during migraine attacks.
Trial: NCT05843968
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 doses of rituximab 375 mg/m\^2(maximum 500mg/day) at 6 months intervals.~Half an hour before rituximab infusion: oral acetaminophen 15mg/kg, oral or intramuscular antihistamine, methylprednisolone 2mg/kg IV. Trimethoprim-sulfamethoxazole should be administered orally from the initiation of rituximab therapy until peripheral-blood B cell recovery to prevent pneumocystis infection.
Trial: NCT05843968
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate Mofetil 20-30 mg/kg/day BID,then adjust the dosage of drugs(maximum 2g/day) to maintian the concentration for MPA-AUC is 30-50μg.h/ml. Total duration:1year.~Steroids dose:1.5mg/kg(maximum 40mg) qod for 2 weeks and gradually taper by 0.3 mg/kg every 2 weeks
Trial: NCT05359263
Drug: Dapagliflozin 10 mg
RxNorm normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The intervention arm consists of dapagliflozin 10 mg orally once daily
Trial: NCT04925414
Drug: oxygenotherapy
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High concentration mask delivering 15L/min of oxygen
Trial: NCT04925414
Drug: placebo air aerosol
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High concentration mask delivering 15L/min of air
Trial: NCT05924100
Drug: Luspatercept Injection [Reblozyl]
RxNorm normalized name: luspatercept Injection [Reblozyl]
DrugBank: Luspatercept (DB12281)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eligible subjects will receive luspatercept (ACE-536): starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (21 days; Q3W). Dose levels can be increased in a stepwise manner beyond the starting dose to 1.33 mg/kg, and up to a maximum of 1.75 mg/kg (with a maximum total dose of 168 mg).~All subjects who have received at least one dose of luspatercept should undergo follow-up evaluations after day 169 with Assessment visits every 24 weeks (168 days) up to 2 years to evaluate evidence of clinical benefit.
Trial: NCT05870501
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5mg/kg IV infusion
Trial: NCT05870501
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.045mg/kg IV infusion
Trial: NCT05655221
Drug: B1344
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: multi-site abdominal s.c. injections (maximum 2 mL at each site)
Trial: NCT06080100
Drug: Xenon
RxNorm normalized name: xenon
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhalation of xenon in a sub-narcotic dosage
Trial: NCT05764798
Drug: Experimental group: Shugan Jieyu Capsule combined with zolpidem
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Shugan Jieyu capsule and zolpidem orally for 8 consecutive weeks
Trial: NCT05764798
Drug: Control group: Placebo combined with zolpidem
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo and zolpidem orally for 8 consecutive weeks
Trial: NCT04983940
Drug: Jatenzo
RxNorm normalized name: Jatenzo
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 237 mg soft gel capsule taken twice a day by mouth with food.
Trial: NCT06393517
Drug: PF-06954522 IR (Formulation 1)
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth
Trial: NCT06393517
Drug: PF-06954522 MR (Formulation 2)
RxNorm normalized name: chloroprocaine
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth.
Trial: NCT06393517
Drug: PF-06954522 MR (Formulation 3)
RxNorm normalized name: hypromellose
DrugBank: Hypromellose (DB11075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth
Trial: NCT04935879
Drug: Inclacumab
RxNorm normalized name: Inclacumab
DrugBank: Inclacumab (DB12246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
Trial: NCT06513364
Drug: WH002
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group A（ddWH002-ddEC）： Regimen for Group A during Cycles 1-Cycles 4:WH002， 260 mg/m² administered intravenously on Day 1, with a cycle length of 2 weeks (Q2W), repeated for a total of 4 cycles.~Regimen for Group A during Cycles 5-Cycles 8:~• Epirubicin Hydrochloride 90 mg/m² and Cyclophosphamide for Injection 600 mg/m², both administered intravenously on Day 1, with each cycle lasting 2 weeks (Q2W), continued for 4 consecutive cycles.
Trial: NCT06513364
Drug: paclitaxel injection
RxNorm normalized name: paclitaxel Injection
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Group B (ddP-ddEC):~Regimen for Group B during Cycles C1-C4:~• Paclitaxel Injection (Paclitaxel®) 175 mg/m², administered intravenously on Day 1, with a cycle duration of 2 weeks (Q2W), repeated for a total of 4 cycles.~Regimen for Group B during Cycles C5-C8:~• Epirubicin Hydrochloride 90 mg/m² and Cyclophosphamide for Injection 600 mg/m², both administered intravenously on Day 1, with cycles recurring every 2 weeks (Q2W), for a series of 4 cycles.
Trial: NCT06030895
Drug: Sorafenib Tablets
RxNorm normalized name: Sorafenib Tablets
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib Tablets (200 -400 mg) twice daily
Trial: NCT06717243
Drug: Carboplatin/Cisplatin -Etoposide - Atezolizumab
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This intervention represents the standard-of-care first-line treatment regimen for extensive-stage small cell lung cancer (ES-SCLC). The regimen includes:~Carboplatin or Cisplatin: Platinum-based chemotherapeutic agents that cause DNA cross-linking, leading to tumor cell death.~Etoposide: A topoisomerase II inhibitor that prevents DNA replication and tumor growth.~Atezolizumab: A PD-L1 immune checkpoint inhibitor that enhances the immune system's ability to detect and destroy cancer cells.~This combination therapy is administered as part of routine clinical practice. The study does not investigate the efficacy or safety of these drugs but rather focuses on analyzing molecular changes in tumors, such as genomic and epigenetic alterations, to understand mechanisms of treatment resistance. Biospecimens are collected from patients during treatment and progression for detailed analysis.
Trial: NCT06710288
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose: 800 mg/m2 intravenously (IV) Frequency: administered on Day 1, Day 8, and Day 15 of each cycle (every 4 weeks)
Trial: NCT06716645
Drug: Robitussin Maximum Strength Nighttime Cough DM
RxNorm normalized name: DEXTROMETHORPHAN HYDROBROMIDE 30 mg in 20 mL / DOXYLAMINE SUCCINATE 12.5 mg in 20 mL ORAL SOLUTION [Robitussin Maximum Strength Nighttime Cough DM]
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan Hydrobromide, USP 30 mg and Doxylamine Succinate, USP 12.5 mg
Trial: NCT06719011
Drug: Cagrilintide B
RxNorm normalized name: Cagrilintide
DrugBank: Cagrilintide (DB18887)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive Cagrilintide B administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.
Trial: NCT06718686
Drug: Rifaximin SSD 40 mg IR tablet
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug therapy vs placebo
Trial: NCT06718634
Drug: BL-M08D1
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Trial: NCT06715085
Drug: Plasma Rich in Growth Factors (PRGF)
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The PRGF application consists of three series of infiltrations in the intervertebral disc, epidural space and facets, with a frequency of two weeks.
Trial: NCT06718257
Drug: Gemcitabine combined with cisplatin or oxaliplatin
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (1000 mg/m², day 1 and 8) and cisplatin (75 mg/m², day 1) or oxaliplatin (85 mg/m², day 1)
Trial: NCT06718933
Drug: SHR-A1811
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADC
Trial: NCT06718933
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bevacizumab biosimilar
Trial: NCT06718933
Drug: Pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-HER2 inhibitor
Trial: NCT06717698
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide will be administered subcutaneously.
Trial: NCT06710223
Drug: SD-101
RxNorm normalized name: Alphanine SD
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toll-like receptor 9 (TLR9) agonist
Trial: NCT06710223
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CTLA4